These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
443 related articles for article (PubMed ID: 26059860)
1. The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study. Younossi ZM; Stepanova M; Pol S; Bronowicki JP; Carrieri MP; Bourlière M Liver Int; 2016 Jan; 36(1):42-8. PubMed ID: 26059860 [TBL] [Abstract][Full Text] [Related]
2. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis. Reddy KR; Bourlière M; Sulkowski M; Omata M; Zeuzem S; Feld JJ; Lawitz E; Marcellin P; Welzel TM; Hyland R; Ding X; Yang J; Knox S; Pang P; Dvory-Sobol H; Subramanian GM; Symonds W; McHutchison JG; Mangia A; Gane E; Mizokami M; Pol S; Afdhal N Hepatology; 2015 Jul; 62(1):79-86. PubMed ID: 25846144 [TBL] [Abstract][Full Text] [Related]
3. Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials. Tam E; Luetkemeyer AF; Mantry PS; Satapathy SK; Ghali P; Kang M; Haubrich R; Shen X; Ni L; Camus G; Copans A; Rossaro L; Guyer B; Brown RS; Liver Int; 2018 Jun; 38(6):1010-1021. PubMed ID: 29091342 [TBL] [Abstract][Full Text] [Related]
4. Patient-reported Outcomes in Asian Patients With Chronic Hepatitis C Treated With Ledipasvir and Sofosbuvir. Younossi ZM; Stepanova M; Chan HLY; Lee MH; Yu ML; Dan YY; Choi MS; Henry L Medicine (Baltimore); 2016 Mar; 95(9):e2702. PubMed ID: 26945356 [TBL] [Abstract][Full Text] [Related]
5. Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study. Younossi ZM; Stepanova M; Zeuzem S; Dusheiko G; Esteban R; Hezode C; Reesink HW; Weiland O; Nader F; Hunt SL J Hepatol; 2014 Aug; 61(2):228-34. PubMed ID: 24713186 [TBL] [Abstract][Full Text] [Related]
6. Sofosbuvir and ledipasvir improve patient-reported outcomes in patients co-infected with hepatitis C and human immunodeficiency virus. Younossi ZM; Stepanova M; Sulkowski M; Naggie S; Henry L; Hunt S J Viral Hepat; 2016 Nov; 23(11):857-865. PubMed ID: 27291391 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis. Tao T; Jiang X; Chen Y; Song Y Int J Infect Dis; 2017 Feb; 55():56-71. PubMed ID: 28040553 [TBL] [Abstract][Full Text] [Related]
8. Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany. Buggisch P; Wursthorn K; Stoehr A; Atanasov PK; Supiot R; Lee J; Ting J; Petersen J PLoS One; 2019; 14(4):e0214795. PubMed ID: 30946776 [TBL] [Abstract][Full Text] [Related]
9. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials. Younossi ZM; Stepanova M; Marcellin P; Afdhal N; Kowdley KV; Zeuzem S; Hunt SL Hepatology; 2015 Jun; 61(6):1798-808. PubMed ID: 25627448 [TBL] [Abstract][Full Text] [Related]
10. Sofosbuvir-ledipasvir with or without ribavirin for chronic hepatitis C genotype-1 and 6: real-world experience in Vietnam. Thu Thuy PT; Bunchorntavakul C; Tan Dat H; Palecki J; Reddy KR Antivir Ther; 2018; 23(5):415-423. PubMed ID: 29303482 [TBL] [Abstract][Full Text] [Related]
11. Ledipasvir/sofosbuvir treatment of hepatitis C virus is associated with reduction in serum apolipoprotein levels. Younossi ZM; Elsheikh E; Stepanova M; Gerber L; Nader F; Stamm LM; Brainard DM; McHutchinson JG J Viral Hepat; 2015 Dec; 22(12):977-82. PubMed ID: 26280786 [TBL] [Abstract][Full Text] [Related]
12. Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin. Globke B; Raschzok N; Teegen EM; Pratschke J; Schott E; Eurich D Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27943544 [TBL] [Abstract][Full Text] [Related]
13. Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. Younossi ZM; Stepanova M; Afdhal N; Kowdley KV; Zeuzem S; Henry L; Hunt SL; Marcellin P J Hepatol; 2015 Aug; 63(2):337-45. PubMed ID: 25795586 [TBL] [Abstract][Full Text] [Related]
14. Multicenter Experience using Ledipasvir/Sofosbuvir ± RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment. Aqel B; Leise M; Vargas HE; Watt KD; Keaveny AP; Zhang N; Zhang N; Pungpapong S Ann Hepatol; 2018 Aug; 17(5):815-821. PubMed ID: 30145562 [TBL] [Abstract][Full Text] [Related]
15. Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy. Suda G; Ogawa K; Yamamoto Y; Katagiri M; Furuya K; Kumagai K; Konno J; Kimura M; Kawagishi N; Ohara M; Umemura M; Ito J; Izumi T; Nakai M; Sho T; Natsuizaka M; Morikawa K; Tsubota A; Shimada N; Iio E; Tanaka Y; Sakamoto N; J Gastroenterol; 2017 Oct; 52(10):1122-1129. PubMed ID: 28315983 [TBL] [Abstract][Full Text] [Related]
16. Cost-utility analysis of ledipasvir/sofosbuvir for the treatment of genotype 1 chronic hepatitis C in Japan. Igarashi A; Tang W; Guerra I; Marié L; Cure S; Lopresti M Curr Med Res Opin; 2017 Jan; 33(1):11-21. PubMed ID: 27609424 [TBL] [Abstract][Full Text] [Related]
17. Patient-Reported Outcomes of Elderly Adults with Chronic Hepatitis C Treated with Interferon- and Ribavirin-Free Regimens. Younossi ZM; Stepanova M; Nader F; Henry L J Am Geriatr Soc; 2016 Feb; 64(2):386-93. PubMed ID: 26825683 [TBL] [Abstract][Full Text] [Related]
18. Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens. Younossi ZM; Stepanova M; Nader F; Jacobson IM; Gane E; Nelson D; Lawitz E; Hunt SL Hepatology; 2014 Jun; 59(6):2161-9. PubMed ID: 24710669 [TBL] [Abstract][Full Text] [Related]
19. Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials. Alqahtani SA; Afdhal N; Zeuzem S; Gordon SC; Mangia A; Kwo P; Fried M; Yang JC; Ding X; Pang PS; McHutchison JG; Pound D; Reddy KR; Marcellin P; Kowdley KV; Sulkowski M Hepatology; 2015 Jul; 62(1):25-30. PubMed ID: 25963890 [TBL] [Abstract][Full Text] [Related]
20. Sofosbuvir-based regimens in the treatment of patients with chronic hepatitis C virus infection: Real-world efficacy in Thailand. Sirinawasatien A; Techasirioangkun T PLoS One; 2020; 15(2):e0229517. PubMed ID: 32106270 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]